Merck Likes Biosimilars, But Not ESAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck is dropping development of one of its first biosimilar drug candidates, a pegylated version of Amgen's erythropoiesis stimulating agent Aranesp (darbepoetin alfa), due to cardiovascular risks associated with the drugs and potential regulatory requirements
You may also be interested in...
Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO
The Government Accountability Office is issuing a cautionary note that Medicare's upcoming prospective payment system for end-stage renal disease might impair access to drugs for some demographic groups
Merck R&D: A Jam-Packed Pipeline, But Much Of It Is Wait-And-See
With Schering-Plough's research now tucked snugly in with Merck's, the combined company met with analysts and investors for its widely anticipated R&D overview May 11. Even as management laid out a deep mid- to late-stage pipeline especially rich in cardiovascular products, executives provided little in the way of scientific news
Merck R&D: A Jam-Packed Pipeline, But Much Of It Is Wait-And-See
With Schering-Plough's research now tucked snugly in with Merck's, the combined company met with analysts and investors for its widely anticipated R&D overview May 11. Even as management laid out a deep mid- to late-stage pipeline especially rich in cardiovascular products, executives provided little in the way of scientific news